Novartis and Merck Could Boost One Another to New Heights
After rumors abound that Novartis will shop its animal health unit, is an asset swap better than a sale?
Gilead's Sofosbuvir Gains FDA Approval, Attracts Patent Battle
Race for new hepatitis C therapy riddled with patent complications.
Merck, Johnson & Johnson Slide on the Dow's Dip
Merck falls among a slow day for both Big Pharma and blue-chip stocks.
Eli Lilly Struggles for Pipeline Success
Edivoxetine failure dampens Lilly's R&D efforts